Roche, GO Therapeutics to Develop Antibody-Based Cancer Treatments

Roche plans to develop new cancer treatments based on antibody technology for which it has secured an exclusive worldwide license from GO Therapeutics, under a collaboration that the Cambridge, MA, startup said could generate for it more than $195 million.The license agreement covers antibodies aimed at a novel undisclosed cancer-specific target, with the goal of developing and commercializing a new glycotargeting bispecific antibody.GO’s approach to fighting cancer centers on stopping the